Abstract
AbstractPrior authorization is a process that health insurance companies use to determine if a patient’s health insurance will cover certain medical treatments, procedures, or medications. Prior authorization requests are common in adult congenital and pediatric cardiology (ACPC) due to need for advanced diagnostics, complex procedures, disease-specific medications, and the heterogeneity of the ACPC population. Prior authorizations in ACPC are rarely denied, but nonetheless, they are often accompanied by significant administrative burden on clinical care teams and delays in patient care. Prior authorizations have been implicated in worsening care inequities. The prior authorization process is insurer specific with differences between commercial and public insurers. Prior authorization rejections were previously found to be more common for women, racial minorities, those with low education, and in low-income groups. Prior authorization unduly burdens routine diagnostics, routine interventional and surgical procedures, and routine cardiac specific medication use in the ACPC population. This manuscript highlights the burdens of prior authorization and advocates for the elimination of prior authorization for ACPC patients.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Pediatrics, Perinatology and Child Health
Reference37 articles.
1. eviCore prior authorization program|blue cross and blue shield of Texas. https://www.bcbstx.com/provider/clinical/clinical-resources/evicore. Accessed 25 Dec 2022
2. Watson I. The utilization review process and the origins of medical necessity. https://www.mcg.com/blog/2018/06/21/utilization-review-medical-necessity/. Accessed 25 Dec 2022
3. Myers KD et al (2019) Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes 12(8):e005404. https://doi.org/10.1161/CIRCOUTCOMES.118.005404
4. 2016 AMA prior authorization physician survey. https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/government/advocacy/2016-pa-survey-results.pdf. Accessed 25 Dec 2022
5. Barriers to new medications for cardiovascular disease: insights from cardiosurve. American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2017/02/21/12/42/barriers-to-new-medications-for-cardiovascular-disease-insights-from-cardiosurve. Accessed 25 Dec 2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献